Pharma giant Mylan has gotten considerable flak for raising the price of the life-saving EpiPen device more than 500% over the course of a decade. It even settled a lawsuit with the U.S. government for $465 million over overcharging Medicaid, the public health program for low-income individuals. But it doesn’t look like the massive legal payout will affect the company’s top executives.

Had the cost of the settlement been incorporated into Mylan’s adjusted earnings, officials like CEO Heather Bresch would have taken big haircuts in their bonuses, according to the Wall Street Journal. But Mylan’s way of reporting earnings doesn’t actually take such costs into account. Read More